Anixa Biosciences ROA 2024

Anixa Biosciences Aktienanalyse

What does Anixa Biosciences do?

Anixa Biosciences Inc is a biotechnology company focused on the development and commercialization of cancer therapeutics. The company is headquartered in San Jose, California and was founded in 1982. The history of Anixa Biosciences Inc began as a subsidiary of VaxGen Inc, a now dissolved biotechnology company. Originally, Anixa focused on the development of vaccines for infectious diseases before shifting its focus to cancer therapeutics. Since 2016, Anixa Biosciences Inc has made rapid progress, particularly in the field of cancer immunotherapy. The company has formed several partnerships with other major pharmaceutical companies such as Cleveland Clinic and OntoChem to accelerate the development of treatments for various types of cancer. Anixa Biosciences Inc's business model is based on the development and commercialization of patented cancer therapeutics. Anixa has specialized in the development of immunotherapeutics based on its own proprietary technology platform. The company has specialized in three areas: cancer detection, immunotherapy, and antibody production. In cancer detection, the company is working on the development of diagnostic tools that enable doctors to detect and treat cancer at an early stage. In the field of immunotherapy, Anixa has developed various therapeutics that stimulate the body's immune system to attack and destroy cancer cells. The company has specifically developed immunotherapeutics that specialize in targeted attacks on cancer cells. In antibody production, Anixa focuses on the development of monoclonal antibodies that specifically target tumor cells. These antibodies can be used to identify and isolate cancer cells. Additionally, they can be used as carriers for drugs to provide targeted therapies against tumor cells. Another product of Anixa Biosciences Inc is the CchekTM blood test, which was developed for the detection of breast, ovarian, and prostate cancer. The blood test is based on the discovery of specific biomarkers that can indicate an increased presence of cancer cells in blood samples. In 2019, Anixa announced its entry into the rapidly growing market for in-vitro diagnostics. This market includes the development and commercialization of diagnostic tools used for disease identification and monitoring disease progression. Anixa plans to expand its expertise in cancer diagnostics to other disease areas such as cardiovascular diseases and neurological diseases. Overall, Anixa Biosciences Inc has a diverse portfolio of products specializing in the development of cancer therapeutics, diagnostic tools, and immune competence. The company works closely with established research and development companies to enhance its technologies and create new products. Anixa positions itself as an innovative and future-oriented company in the biotechnology industry. Anixa Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Anixa Biosciences's Return on Assets (ROA)

Anixa Biosciences's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Anixa Biosciences's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Anixa Biosciences's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Anixa Biosciences’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Anixa Biosciences Stock

What is the Return on Assets (ROA) of Anixa Biosciences this year?

The Return on Assets (ROA) of Anixa Biosciences is -0.38 undefined this year.

What was the ROA of Anixa Biosciences compared to the previous year?

The ROA of Anixa Biosciences has increased by -14.04% compared to the previous year.

What consequences do high ROA have for investors of Anixa Biosciences?

A high ROA is advantageous for investors of Anixa Biosciences, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Anixa Biosciences?

A low ROA can be unfavorable for investors of Anixa Biosciences as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Anixa Biosciences affect the company?

An increase in ROA of Anixa Biosciences can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Anixa Biosciences impact the company?

A reduction in the ROA of Anixa Biosciences can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Anixa Biosciences?

Some factors that can influence the ROA of Anixa Biosciences include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Anixa Biosciences important for investors?

The ROA of Anixa Biosciences is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Anixa Biosciences take to improve ROA?

To improve ROA, Anixa Biosciences can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Anixa Biosciences pay?

Over the past 12 months, Anixa Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Anixa Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Anixa Biosciences?

The current dividend yield of Anixa Biosciences is .

When does Anixa Biosciences pay dividends?

Anixa Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Anixa Biosciences?

Anixa Biosciences paid dividends every year for the past 0 years.

What is the dividend of Anixa Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Anixa Biosciences located?

Anixa Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Anixa Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Anixa Biosciences from 4/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/29/2024.

When did Anixa Biosciences pay the last dividend?

The last dividend was paid out on 4/29/2024.

What was the dividend of Anixa Biosciences in the year 2023?

In the year 2023, Anixa Biosciences distributed 0 USD as dividends.

In which currency does Anixa Biosciences pay out the dividend?

The dividends of Anixa Biosciences are distributed in USD.